Learn More
AIMS To describe baseline characteristics and visual outcome for eyes treated with ranibizumab for diabetic macular oedema (DMO) from a multicentre database. METHODS Structured clinical data were(More)
AIM To assess the rate of 'treatment-requiring diabetic macular oedema (DMO)' in eyes for the two  years before and after cataract surgery. METHODS Multicentre national diabetic retinopathy (DR)(More)